A similar study combining the modified herpes simplex virus talimogene laherparepvec (T-VEC) with CTLA-4 blockade was conducted in a melanoma mouse model, for which an increased efficacy of the combination therapy was reported by the authors [46]. This evidence concerns the gene CTLA4 and melanoma.